SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Sera Prognostics (NASDAQ: SERA) reported its Q1 2025 financial results, showing revenue of $38,000 compared to zero in Q1 2024. The company posted a net loss of $8.2 million, slightly higher than the $8.1 million loss in the prior year. Total operating expenses increased to $9.3 million from $9.1 million year-over-year.
Following successful PRIME study results, Sera is increasing engagement with payors and pursuing Medicaid opportunities across three states for PreTRM test implementation pilots. The company maintains a strong financial position with $114.2 million in cash and equivalents. R&D expenses decreased 9% to $3.3 million, while SG&A expenses rose to $5.9 million from $5.4 million as the company invests in strategic growth initiatives.
Sera Prognostics (NASDAQ: SERA) ha comunicato i risultati finanziari del primo trimestre 2025, con un fatturato di 38.000 dollari rispetto a zero nel primo trimestre 2024. L'azienda ha registrato una perdita netta di 8,2 milioni di dollari, leggermente superiore agli 8,1 milioni di dollari di perdita dell'anno precedente. Le spese operative totali sono aumentate a 9,3 milioni di dollari rispetto ai 9,1 milioni dell'anno precedente.
In seguito ai risultati positivi dello studio PRIME, Sera sta intensificando il coinvolgimento con i pagatori e sta esplorando opportunità Medicaid in tre stati per l'implementazione pilota del test PreTRM. L'azienda mantiene una solida posizione finanziaria con 114,2 milioni di dollari in liquidità e equivalenti. Le spese per R&S sono diminuite del 9% a 3,3 milioni di dollari, mentre le spese SG&A sono salite a 5,9 milioni di dollari dai 5,4 milioni, in quanto l'azienda investe in iniziative strategiche di crescita.
Sera Prognostics (NASDAQ: SERA) reportó sus resultados financieros del primer trimestre de 2025, mostrando ingresos de 38,000 dólares en comparación con cero en el primer trimestre de 2024. La compañía registró una pérdida neta de 8.2 millones de dólares, ligeramente superior a la pérdida de 8.1 millones del año anterior. Los gastos operativos totales aumentaron a 9.3 millones de dólares desde 9.1 millones año tras año.
Tras los exitosos resultados del estudio PRIME, Sera está aumentando su interacción con los pagadores y buscando oportunidades de Medicaid en tres estados para pilotos de implementación de la prueba PreTRM. La compañía mantiene una sólida posición financiera con 114.2 millones de dólares en efectivo y equivalentes. Los gastos en I+D disminuyeron un 9% a 3.3 millones, mientras que los gastos SG&A aumentaron a 5.9 millones desde 5.4 millones, ya que la empresa invierte en iniciativas estratégicas de crecimiento.
Sera Prognostics (NASDAQ: SERA)는 2025년 1분기 재무 실적을 발표했으며, 2024년 1분기 0달러에서 38,000달러의 매출을 기록했습니다. 회사는 820만 달러의 순손실을 보고했으며, 이는 전년도의 810만 달러 손실보다 약간 증가한 수치입니다. 총 영업비용은 전년 대비 910만 달러에서 930만 달러로 증가했습니다.
성공적인 PRIME 연구 결과에 따라, Sera는 보험사와의 협력을 강화하고 세 개 주에서 Medicaid 기회를 모색하며 PreTRM 테스트 파일럿 도입을 추진하고 있습니다. 회사는 1억 1,420만 달러의 현금 및 현금성 자산을 보유하며 안정적인 재무 상태를 유지하고 있습니다. 연구개발 비용은 9% 감소하여 330만 달러가 되었고, SG&A 비용은 540만 달러에서 590만 달러로 증가했는데, 이는 회사가 전략적 성장 이니셔티브에 투자하고 있기 때문입니다.
Sera Prognostics (NASDAQ : SERA) a publié ses résultats financiers du premier trimestre 2025, affichant un chiffre d'affaires de 38 000 $ contre zéro au premier trimestre 2024. La société a enregistré une perte nette de 8,2 millions de dollars, légèrement supérieure à la perte de 8,1 millions de dollars de l'année précédente. Les dépenses d'exploitation totales ont augmenté pour atteindre 9,3 millions de dollars contre 9,1 millions d'une année sur l'autre.
Suite aux résultats positifs de l'étude PRIME, Sera renforce son engagement avec les payeurs et explore des opportunités Medicaid dans trois États pour des projets pilotes d'implémentation du test PreTRM. La société conserve une solide position financière avec 114,2 millions de dollars en liquidités et équivalents. Les dépenses en R&D ont diminué de 9 % pour s'établir à 3,3 millions, tandis que les dépenses SG&A ont augmenté à 5,9 millions contre 5,4 millions, la société investissant dans des initiatives stratégiques de croissance.
Sera Prognostics (NASDAQ: SERA) meldete seine Finanzergebnisse für das erste Quartal 2025 mit einem Umsatz von 38.000 US-Dollar im Vergleich zu null im ersten Quartal 2024. Das Unternehmen verzeichnete einen Nettoverlust von 8,2 Millionen US-Dollar, etwas höher als der Verlust von 8,1 Millionen US-Dollar im Vorjahr. Die gesamten Betriebskosten stiegen von 9,1 Millionen auf 9,3 Millionen US-Dollar im Jahresvergleich.
Nach erfolgreichen Ergebnissen der PRIME-Studie intensiviert Sera die Zusammenarbeit mit Kostenträgern und verfolgt Medicaid-Möglichkeiten in drei Bundesstaaten für Pilotprojekte zur Implementierung des PreTRM-Tests. Das Unternehmen hält eine starke Finanzlage mit 114,2 Millionen US-Dollar in bar und liquiden Mitteln. Die F&E-Ausgaben sanken um 9 % auf 3,3 Millionen US-Dollar, während die SG&A-Ausgaben von 5,4 Millionen auf 5,9 Millionen US-Dollar stiegen, da das Unternehmen in strategische Wachstumsinitiativen investiert.
- First revenue generation of $38,000 in Q1 2025 compared to zero in Q1 2024
- Strong cash position of $114.2 million
- 9% reduction in R&D expenses due to decreased PRIME study costs
- Expansion into Medicaid market which represents approximately 50% of market opportunity
- Net loss increased to $8.2 million from $8.1 million year-over-year
- Operating expenses increased to $9.3 million from $9.1 million
- SG&A expenses rose by $0.5 million to $5.9 million
Insights
Sera begins revenue generation ($38K) but losses continue ($8.2M); maintains strong cash position ($114.2M) providing 3.5 years runway.
Sera Prognostics reported its first revenue of
Operating expenses increased slightly to
The quarterly net loss of
Strategically, Sera is engaging with payors following their successful PRIME study and pursuing Medicaid opportunities, which they identify as representing half their market potential. The company has initiated discussions with Medicaid plans across three states for PreTRM implementation pilots, which could validate their test-and-treat approach.
The addition of Jeff Elliott to their Board signals their focus on commercial scaling expertise as they transition from R&D to commercial operations. While revenue generation has begun, it remains nominal compared to expenses, reflecting very early-stage commercialization of their pregnancy biomarker test.
Recent Highlights:
- Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrators.
- Pursuing Medicaid opportunity, which represents approximately half of the market opportunity for Sera's PreTRM® Test; in discussions with several Medicaid plans across three states for PreTRM test implementation pilots.
- Expecting to have strong presence at upcoming American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting May 16-18. Sera plans to meet with attendees to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm.
- Appointed Jeff Elliott to Board of Directors, making talented board deeper with his breadth and depth of expertise in commercially scaling companies in our sector.
"Following the results of our full PRIME pivotal study being publicized we are leveraging them by engaging with key plan providers in focused geographic regions hard hit by premature birth," said Zhenya Lindgardt, President and CEO of Sera Prognostics. "While it will take some time to evolve, we anticipate that Medicaid providers in those areas will see the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test."
First Quarter 2025 Financial Results
First quarter 2025 revenue was
Total operating expenses were
Research and development expenses for the first quarter of 2025 were
Selling, general and administrative expenses for the first quarter of 2025 were
Net loss for the quarter was
As of March 31, 2025, the Company had cash, cash equivalents, and available-for-sale securities of approximately
Conference Call Information
Sera Prognostics will host a corresponding conference call and live webcast today to discuss first quarter 2025 operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing the following:
US domestic callers: (800) 836-8184
International callers: (646) 357-8785
Webcast Registration Link: https://app.webinar.net/AgbMlY25y3q
Live audio of the webcast will be available online from the Investors page of the Company's website at www.sera.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company elevating engagement with payors and plan administrators; the Company's discussions with several Medicaid plans across three states for PreTRM test implementation pilots; the Company's plans to cultivate interest in continued investigator-initiated evidence generation for the PreTRM test-and-treat paradigm; Medicaid providers seeing the positive impact PreTRM can make in healthcare cost savings and patient outcomes, furthering adoption of the test; the date and time and content of the Company's quarterly earnings release and conference call; availability of the live audio of the conference call on the Company's website; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Contact
Investor Contact
Peter DeNardo, CapComm Partners
peter@capcommpartners.com
+1 (415) 389-6400
SERA PROGNOSTICS, INC. Condensed Statements of Operations (unaudited) (in thousands, except share and per share data) | ||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2025 | 2024 | |||||||
Revenue | $ | 38 | $ | — | ||||
Operating expenses: | ||||||||
Cost of revenue | 40 | 17 | ||||||
Research and development | 3,334 | 3,683 | ||||||
Selling and marketing | 1,470 | 1,227 | ||||||
General and administrative | 4,444 | 4,170 | ||||||
Total operating expenses | 9,288 | 9,097 | ||||||
Loss from operations | (9,250) | (9,097) | ||||||
Interest expense | (4) | (9) | ||||||
Other income, net | 1,067 | 1,009 | ||||||
Net loss | $ | (8,187) | $ | (8,097) | ||||
Net loss per share, basic and diluted | $ | (0.20) | $ | (0.25) | ||||
Weighted-average shares outstanding, basic and diluted | 41,968,076 | 32,220,038 | ||||||
SERA PROGNOSTICS, INC. Condensed Balance Sheets (unaudited) (in thousands) | ||||||||
March 31, | December 31, | |||||||
2025 | 2024 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 5,230 | $ | 4,043 | ||||
Marketable securities | 40,967 | 42,193 | ||||||
Accounts receivable | 25 | 34 | ||||||
Prepaid expenses and other current assets | 1,061 | 1,330 | ||||||
Total current assets | 47,283 | 47,600 | ||||||
Property and equipment, net | 1,312 | 1,239 | ||||||
Long-term marketable securities | 68,004 | 21,973 | ||||||
Intangible assets, net | 997 | 1,026 | ||||||
Other assets | 588 | 737 | ||||||
Total assets | $ | 118,184 | $ | 72,575 | ||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 1,207 | $ | 1,969 | ||||
Accrued and other current liabilities | 1,892 | 2,384 | ||||||
Finance lease obligation, current portion | 81 | 194 | ||||||
Deferred revenue | 20,221 | 20,223 | ||||||
Total current liabilities | 23,401 | 24,770 | ||||||
Finance lease obligation, net of current portion | — | 2 | ||||||
Total liabilities | 23,401 | 24,772 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Common stock, Class A and Class B | 4 | 3 | ||||||
Additional paid-in capital | 382,684 | 327,534 | ||||||
Accumulated other comprehensive income | 76 | 60 | ||||||
Accumulated deficit | (287,981) | (279,794) | ||||||
Total stockholders' equity | 94,783 | 47,803 | ||||||
Total liabilities and stockholders' equity | $ | 118,184 | $ | 72,575 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-reports-first-quarter-2025-financial-results-302449108.html
SOURCE Sera Prognostics, Inc.
FAQ
What were Sera Prognostics (SERA) Q1 2025 earnings results?
How much cash does Sera Prognostics (SERA) have as of Q1 2025?
What is Sera Prognostics' (SERA) strategy for market expansion?
How did Sera Prognostics' (SERA) operating expenses change in Q1 2025?
What were the key developments for Sera Prognostics (SERA) in Q1 2025?
